Key facts
- This page summarizes bluebird bio, Inc.'s Form 4 filing for 2seventy bio, Inc. (TSVT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Nov 2021, 19:27.
bluebird bio, Inc. - 03 Nov 2021 Form 4 Insider Report for 2seventy bio, Inc. (TSVT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TSVT
- Reported as of
- 03 Nov 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Nov 2021, 19:27:15 UTC
- Prior SEC filing
- 18 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Helen Fu, SVP, General Counsel of bluebird bio, Inc.
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
bluebird bio, Inc. filed Form 4 for 2seventy bio, Inc. (TSVT) on 08 Nov 2021.
Change
- Previous filing in this sequence was filed on 18 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSVT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +23,368,988
- Change %
- +23368988%
- Price
- $0.000000
- Shares after
- 23,369,088
- Date
- 03 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
TSVT
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -23,369,088
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 04 Nov 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
bluebird bio, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
On November 3, 2021, the Issuer issued 23,368,988 shares of its common stock to its sole stockholder, bluebird bio, Inc. ("bluebird").
Footnote F2
On November 4, 2021, bluebird distributed all of the issued and outstanding shares of the Issuer's common stock to its stockholders on a pro rata basis, with each bluebird stockholder receiving one share of the Issuer's common stock for every three shares of bluebird common stock, as part of the separation of the Issuer from bluebird into two independent public companies.